Truist raised the firm’s price target on Argenx (ARGX) to $660 from $540 and keeps a Buy rating on the shares after its Q3 earnings beat. The company delivered 11th consecutive sequential growth quarter and the stock offers the most enviable I&I – inflammation and immunology – pipeline in the industry, with multiple data read-outs over the next 12-18 months, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- PayPal, Estee Lauder downgraded: Wall Street’s top analyst calls
- Argenx price target raised to $665 from $585 at Guggenheim
- Argenx price target raised to $688 from $605 at Raymond James
- Argenx price target raised to $646 from $560 at Oppenheimer
- Argenx price target raised to $620 from $553 at Piper Sandler